Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.67 |
| ▸ | MMP13 | P45452 | 8/20 | 0.67 |
| ▸ | MMP9 | P14780 | 7/20 | 0.67 |
| ▸ | MMP3 | P08254 | 7/20 | 0.67 |
| ▸ | MMP1 | P03956 | 5/20 | 0.67 |
| ▸ | MMP7 | P09237 | 2/20 | 0.67 |
| ▸ | MMP8 | P22894 | 2/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6736584 | 1.00 | MMP2 (0.67) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL7387102 | 0.89 | MMP2 (0.64) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6768375 | 0.89 | MMP2 (0.64) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6733789 | 0.89 | MMP2 (0.64) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6738197 | 0.88 | MMP13 (0.63) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6732456 | 0.88 | MMP13 (0.63) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6741519 | 0.86 | MMP2 (0.60) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6738036 | 0.86 | MMP2 (0.60) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6742257 | 0.84 | MMP13 (0.58) | MMP2MMP13MMP9MMP3MMP1 | |
| SCHEMBL6733022 | 0.84 | MMP13 (0.57) | MMP2MMP13MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | THE PROCTER &GAMBLE COMPANY | 2004-07-22 | — | — | US | claimed |
| US-6696456-B1 | CARBOCYCLIC ACIDS AND SALTS SUCH AS (2S,3R)-3-ETHYLSULFANYL-2-(4'-FLUORO-BIPHENYL-4-SULFONYLAMINO)-3- PHENYLPROPIONIC ACID, USED AS METALLOENZYME ANTAGONISTS FOR THE PROPHYLAXIS OF DEGENERATIVE JOINT DISEASE AND AS WOUND HEALING AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | ADAM17, ADAM9, SI | MMP2 13/4885MMP13 57/4885MMP9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.